Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Osteoarthritis Pain
Latest Information Update: 23 Jul 2024
At a glance
- Drugs LY 3526318 (Primary)
- Indications Pain
- Focus Therapeutic Use
- Acronyms CPMP
- Sponsors Eli Lilly and Company
- 10 Aug 2022 Status changed from active, no longer recruiting to completed.
- 18 Apr 2022 Planned End Date changed from 17 Jun 2022 to 6 Jun 2022.
- 18 Apr 2022 Planned primary completion date changed from 17 Jun 2022 to 6 Jun 2022.